Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests

被引：4

作者：

Serra Elizalde, V. ^{[1
]}

Llop-Guevara, A. ^{[1
]}

Pearson, A. ^{[2
]}

Cruz, C. ^{[1
]}

Castroviejo-Bermejo, M. ^{[1
]}

Chopra, N. ^{[2
]}

Tovey, H. ^{[3
]}

Toms, C. ^{[3
]}

Kriplani, D. ^{[2
]}

Gevensleben, H. ^{[2
]}

Roylance, R. ^{[4
]}

Chan, S. ^{[5
]}

Tutt, A. ^{[6
]}

Skene, A. ^{[7
]}

Evans, A. ^{[8
]}

Davies, H. R. ^{[9
]}

Bliss, J. ^{[10
]}

Nik-Zainal, S. ^{[11
]}

Balmana, J. ^{[12
]}

Turner, N. ^{[13
]}

机构：

[1] Vall dHebron Inst Oncol, Expt Therapeut Grp, Barcelona, Spain

[2] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England

[3] Inst Canc Res, Clin Trials & Stat Unit, London, England

[4] UCLH Univ Coll London Hosp NHS Fdn Trust, Oncol, London, England

[5] Nottingham Univ Hosp Trust, City Campus, Nottingham, England

[6] Kings Coll London, Guys Hosp, Breast Canc Now Res Unit, Ctr Canc, London, England

[7] Royal Bournemouth Hosp, Surg, Bournemouth, Dorset, England

[8] Poole Hosp NHS Fdn Trust, Surg, Poole, Dorset, England

[9] Univ Cambridge, MRC Canc Unit, Cambridge, England

[10] ICR Inst Canc Res, Clin Trials & Stat Unit, London, England

[11] Addenbrookes Treatment Ctr, Dept Med Genet, Cambridge, England

[12] Vall dHebron Inst Oncol, Oncol, Barcelona, Spain

[13] Royal Marsden Hosp NHS Fdn Trust, Breast Unit, London, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

基金：

英国惠康基金;

关键词：

D O I：

10.1016/j.annonc.2021.03.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

下载

页码：S21 / S22

页数：2

共 24 条

[21] The qRT-PCR-Based DNA Homologous Recombination Deficiency 4-Gene Score Predicts Pathologic Complete Response to Platinum-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Zuo, Ke
Yuan, Xiaoying
Liang, Xizi
Lv, Qi
Zhao, Yajing
Yang, Huanhuan
Li, Xingmin
Yang, Wentao
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 297 - 297
[22] The qRT-PCR-Based DNA Homologous Recombination Deficiency 4-Gene Score Predicts Pathologic Complete Response to Platinum-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Zuo, Ke
Yuan, Xiaoying
Liang, Xizi
Lv, Qi
Zhao, Yajing
Yang, Huanhuan
Li, Xingmin
Yang, Wentao
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 297 - 297
[23] Homologous recombination deficiency predicts response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: Secondary analysis of the neocart randomized clinical trial.
Zhang, Liulu
Wu, Zhiyong
Li, Jie
Lin, Ying
Liu, Zhenzhen
Cao, Yin
Zhang, Gangling
Zhang, Yi
Chen, Yuanqi
Gao, Hong-Fei
Yang, Mei
Yang, Ciqiu
Zhu, Teng
Cheng, Min-Yi
Ji, Fei
Li, Jieqing
Wang, Kun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes
Tutt, Andrew
Stephens, Christine
Frewer, Paul
Pierce, Andrew
Rhee, Joon
So, Karen
Ottesen, Lone
Dean, Emma
Hollingsworth, Simon J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 →